Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
The private group taps DualityBio for an EGFR x HER3 ADC.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
